Michael currently serves as Executive Chairman of Oyster Point Pharmaceuticals, Inc. and is additionally developing two early-stage healthcare ventures. He was mostly recently Vice President, Neurostimulation for Allergan, plc after serving as CEO of Oculeve, Inc., which was acquired by Allergan in August 2015. He has experience in medical device and pharmaceutical development in both academic and industrial settings. He received a B.E. degree, magna cum laude, in biomedical engineering from Vanderbilt University; M.S. and Ph.D. degrees in biomedical engineering from Case Western Reserve University; is a graduate of the Stanford University Biodesign Fellowship; and Vision Research Fellowship at Stanford. He has numerous patents and peer-reviewed publications.